Skip to main content

Impulsivity and its Therapeutic Management in Borderline Personality Disorder: a Systematic Review

Psychiatric Quarterly volume 91, pages 1333–1362 (2020)Cite this article

Abstract

No treatment has been approved and recognized as effective in borderline personality disorder (BPD). Impulsivity is a key dimension because it is a predictor of remission but also suicide. The purpose of this review is to establish an inventory on the management of impulsivity in BPD and determine the effective treatments. A systematic review on the PubMed and Ovid databases was conducted up to September 2019 to December 2019 using the PRISMA guidelines. The inclusion criteria were: studies with patients with borderline personality disorder, were published between 1989 and 2019, used English-language and evaluated impulsivity before and after treatment. 41 articles selected were included for pharmacological treatment. 24 articles were found for psychotherapeutic management and one randomized study of transcranial magnetic stimulation. Based on this review, we must focus on psychotherapy in BPD, particularly the schema therapy, dialectical behavioral therapy, psychoeducation, system training of emotional predictability and problem solving and psychotherapy using mentalisation. The use of neuroleptics and mood stabilizers appears to be more effective than antidepressants. Another approach, such as transcranial magnetic stimulation, may prove useful in the near future if this technique is studied further.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Leichsenring F, Leibniz E, Kruse J, New AS, Leweke F. Borderline personality disorder. Lancet. 2011 Jan 1;377:74–84.

    Google Scholar 

  2. Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M. Borderline personality disorder. Lancet. 2004 Jul 31;364:453–61.

    Google Scholar 

  3. National Collaborating Centre for Mental Health. Borderline Disorder: treatment and management. Full Guideline. Clinical Guideline 78. NICE, 2009.

  4. National Health and Medical Research Council. Clinical Practice Guideline for the Management of Borderline Personality Disorder. Melbourne: National Health and Medical Research Council 2012.

  5. Zanarini MC. Psychotherapy of borderline personality disorder. Acta Psychiatr Scand. 2009 Nov;20(5):373–7.

    Google Scholar 

  6. Links PS, Heslegrave R, van Reekum R. Impulsivity: core aspect of borderline personality disorder. J Personal Disord. 1999;13(1):1–9.

    CAS  Google Scholar 

  7. Lis E, Greenfield B, Henry M, Guilé JM, Dougherty G. Neuroimaging and genetics of borderline personality disorder: a review. J Psychiatry Neurosci. 2007;32:162–73.

    Google Scholar 

  8. Soloff PH, Kelly TM, Strotmeyer SJ, et al. Impulsivity, gender and response to fenfluramine challenge in borderline personality disorder. J Psychiatry Neurosci. 2007 May;32(3):162–73.

    Google Scholar 

  9. Stanford MS, Mathias CW, Dougherty DM, Lake SL, Anderson NE, Patton JH. Fifty years of the Barratt impulsiveness scale: an update and review. Personal Individ Differ. 2009;47(5):385–95.

    Google Scholar 

  10. Sebastian A, Jung P, Krause-Utz A, Lieb K, Schmahl C, Tüscher O. Frontal dysfunctions of impulsive control- a systematic review in borderline personality disorder and attention-deficit/hyperactivity disorder. Front Hum Neurosci. 2014 Sep 3;8:698.

    Google Scholar 

  11. Latalova K, Prasko J. Aggression in borderline personality disorder. Psychiatry Q. 2010;81:239–51.

    CAS  Google Scholar 

  12. Mehran F. Description clinique du trouble de la personnalité borderline. In: Mehran F. Traitement du trouble de la personnalité borderline. 2ème éd. Issy-les-Moulineaux:Elsevier Masson SAS; 2011.

  13. de la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol. 1994 Dec;4(4):479–86.

    Google Scholar 

  14. Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002 Dec;159(12):2048–54.

    Google Scholar 

  15. Pascual JC, Soler J, Puigdemont D, Perez-Egea R, Tiana T, Alvarez E, et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry. 2008 Apr;69(4):603–8.

    CAS  Google Scholar 

  16. Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol. 2009 Sep;24(5):270–5.

    Google Scholar 

  17. Nickel MK, Nickel C, Mitterlehner FO, Tritt K, Lahmann C, Leiberich PK, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004 Nov;65(11):1515–9.

    CAS  Google Scholar 

  18. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002 May;63(5):442–6.

    CAS  Google Scholar 

  19. Nosè M, Cipriani A, Biancosino B, Grassi L, Barbui C. Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2006 Nov;21(6):345–53.

    Google Scholar 

  20. Vita A, De Peri L, Sacchetti E. Antipsychotics, Antidepressants, Anticonvulsants, and Placebo on the Symptom Dimensions of Borderline Personality Disorder: A Meta-Analysis of Randomized Controlled and Open-Label Trials. J. Clin Psychopharmacol. 2011;31(5):613–24.

    CAS  Google Scholar 

  21. Ingenhoven TJM, Duivenvoorden HJ. Differential Effectiveness of Antipsychotics in Borderline Personality Disorder: Meta-Analyses of Placebo-Controlled, Randomized Clinical Trials on Symptomatic Outcome Domains. Journal of Clinical Psychopharmacology. 2011 Aug:31(4).

  22. Soloff PH, George A, Nathan S, Schulz PM, Cornelius JR, Herring J, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 1989 Aug;9(4):238–46.

    CAS  Google Scholar 

  23. Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993 May;50(5):377–85.

    CAS  Google Scholar 

  24. Bellino S, Paradiso E, Bozzatello P, Bogetto F. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. J Psychopharmacol. 2010 Mar;24(3):333–9.

    CAS  Google Scholar 

  25. Bellino S, Rinaldi C, Bogetto F. Adaptation of interpersonal psychotherapy to borderline personality disorder: a comparison of combined therapy and single pharmacotherapy. Can J Psychiatr. 2010 Feb;55(2):74–81.

    Google Scholar 

  26. Bozzatello P, Bellino S. Combined therapy with interpersonal psychotherapy adapted for borderline personality disorder: a two-years follow-up. Psychiatry Res. 2016 Jun 30;240:151–6.

    Google Scholar 

  27. Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001 Mar;62(3):199–203.

    CAS  Google Scholar 

  28. Simeon D, Baker B, Chaplin W, Braun A, Hollander E. An open-label trial of Divalproex extended- release in the treatment of borderline personality disorder. CNS Spectrum. 2007 Jun;12(6):439–43.

    Google Scholar 

  29. Nickel MK, Nickel C, Kaplan P, Lahmann C, Mühlbacher M, Tritt K, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005 Mar 1;57(5):495–9.

    CAS  Google Scholar 

  30. Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005 May;19(3):287–91.

    CAS  Google Scholar 

  31. Crawford MJ, Sanatinia R, Barrett B, Cunningham G, Dale O, Ganguli P, et al. The clinical effectiveness and cost-effectiveness of Lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry. 2018 Aug;175(8):756–64.

    Google Scholar 

  32. Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. 2005 Sep;66(9):1111–5.

    CAS  Google Scholar 

  33. Kutcher S, Papatheodorou G, Reiter S, Gardner D. The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol. J Psychiatry Neurosci. 1995 Mar;20(2):113–8.

    CAS  Google Scholar 

  34. Bogenschutz MP, George NH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004 Jan;65(1):104–9.

    CAS  Google Scholar 

  35. Schulz SC, Zanarini MC, Bateman BM, Detach HC, Trzaskoma Q, et al. Olanzapine for the treatment of borderline personality disorder: Variable dose 12-week randomised double-blind placebo-controlled study. Br J psychiatry. 2008;193(6):485–92.

    Google Scholar 

  36. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001 Nov;62(11):849–54.

    CAS  Google Scholar 

  37. Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2011 Oct;72(10):1353–62.

    Google Scholar 

  38. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry. 1999;46(10):1429–35.

    CAS  Google Scholar 

  39. Adityanjee RA, Brown E, Thuras P, Lee S, Schulz SC. Quetiapine in patients with borderline personality disorder: An open-label trial. Ann Clin psychiatry. 2008;20(4):219–26.

    CAS  Google Scholar 

  40. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry. 2006 Jul;67(7):1042–6.

    CAS  Google Scholar 

  41. Van den Eynde F, Senturk V, Naudts K, Vogels C, Bernagie K, Thas O, et al. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol. 2008 Apr;28(2):147–55.

    Google Scholar 

  42. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry. 2005 Oct;66(10):1298–303.

    CAS  Google Scholar 

  43. Black DW, Zanarini MC, Romine A, Shaw M, Allen J, Schulz SC. Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2014 Nov 1;171(11):1174–82.

    Google Scholar 

  44. Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006 May;163(5):833–8.

    Google Scholar 

  45. Friedel RO, Jackson WT, Huston CS, May RS, Kirby NL, Stoves A. Risperidone treatment of borderline personality disorder assessed by a borderline personality disorder-specific outcome measure: a pilot study. J Clin Psychopharmacol. 2008 Jun;28(3):345–7.

    Google Scholar 

  46. Carrasco JL, Palomares N, Marsá MD. Effectiveness and tolerability of long-acting intramuscular risperidone as adjuvant treatment in refractory borderline personality disorder. Psychopharmacology. 2012 Nov;224(2):347–8.

    CAS  Google Scholar 

  47. Bellino S, Bozzatello P, Rinaldi C, Bogetto F. Paliperidone ER in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability. Depress Res Treat. 2011;2011:680194.

    Google Scholar 

  48. Bellino S, Paradiso E, Bogetto F. Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. Psychiatry Res. 2008 Nov 30;161(2):206–12.

    CAS  Google Scholar 

  49. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004 Jul;65(7):903–7.

    CAS  Google Scholar 

  50. Zanarini MC, Frankenburg FR. Omega-3 Fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. Am J psychiatry. 2003;160(1):167–9.

    Google Scholar 

  51. Bozzatello P, Bellino S, Bogetto F. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of association with valproic acid. Eur Neuropsychopharmacol. 2013 Oct;23(2):399.

    Google Scholar 

  52. Bozzatello P, Rocca P, Bellino S. Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: a follow-up study. Clin Drug Investig. 2018 Jan 5;38:367–72.

    CAS  Google Scholar 

  53. Farrell JM, Shaw IA, Webber MA. A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. J Behav Ther Exp Psychiatry. 2009 Jun;40(2):317–28.

    Google Scholar 

  54. Fassbinder E, Schuetze M, Kranich A, Sipos V, Hohagen F, Shaw I, et al. Feasibility of Group Schema Therapy for Outpatients with Severe Borderline Personality Disorder in Germany: A Pilot Study with Three Year Follow-Up. Front Psychol. 2016;7:1851.

    Google Scholar 

  55. Nadort M, Arntz A, Smit JH, Giesen-Bloo J, Eikelenboom M, Spinhoven P, et al. Implementation of outpatient schema therapy for borderline personality disorder: study design. BMC Psychiatry. 2009;9:64.

    Google Scholar 

  56. van den Bosch LM, Koeter MW, Stijnen T, Verheul R, van den Brink W. Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behav Res Ther. 2005 Sep;43(9):1231–41.

    Google Scholar 

  57. Verheul R, Van Den Bosch LM, Koeter MW, De Ridder MA, Stijnen T, van den Brink W. Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in the Netherlands. Br J Psychiatry. 2003 Feb;182:135–40.

    Google Scholar 

  58. Neacsiu AD, Rizvi SL, Linehan MM. Dialectical behavior therapy skills use as a mediator and outcome of treatment for borderline personality disorder. Behav Res Ther. 2010 Sep;48(9):832–9.

    Google Scholar 

  59. Turner RM. Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. Cogn Behav Pract. 2000;7:413–9.

    Google Scholar 

  60. Soler J, Pascual JC, Tiana T, Cebrià A, Barrachina J, Campins MJ, et al. Dialectical behaviour therapy skills training compared to standard group therapy in borderline personality disorder: a 3-month randomised controlled clinical trial. Behav Res Ther. 2009;47:353–8.

    Google Scholar 

  61. Koons CR, Robins CJ, Tweed JL, Lynch TR, Gonzalez AM, Morse JQ, et al. Efficacy of dialectical behaviour therapy in women veterans with borderline personality disorder. Behav Ther. 2001;32:371–90.

    Google Scholar 

  62. Neacsiu AD, Lungu A, Harned MS, Rizvi SL, Linehan MM. Impact of dialectical behavior therapy versus community treatment by experts on emotional experience, expression , acceptance in borderline personality disorder. Behav Res Ther. 2014 Feb;53:47–54.

    Google Scholar 

  63. De Oliveira C, Rahioui H, Smadja M, Gorsane MA, Louppe F. Mentalisation based treatment and borderline personality disorder. L’encéphale. 2017;43:340–5.

    Google Scholar 

  64. Bateman A, Fonagy P. 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. Am J Psychiatry. 2008;165:631–8.

    Google Scholar 

  65. Cottraux J, Note ID, Boutitie F, Milliery M, Genouihlac V, Yao SN, et al. Cognitive therapy versus Rogerian supportive therapy in borderline personality disorder two-year follow-up of a controlled pilot study. Psychother Psychosom. 2009;78:307–16.

    Google Scholar 

  66. Sachse S, Keville S, Feigenbaum J. A feasibility study of mindfulness-based cognitive therapy for individuals with borderline personality disorder. Psychol Psychother. 2011 Jun;84(2):184–200.

    Google Scholar 

  67. Soler J, Elices M, Pascual JC, Martin-Blanco A, Feliu-Soler A, Camona C, et al. Effects of mindfulness training on different components of impulsivity in borderline personality disorder: results from a pilot randomized study. Borderline Personal Disord Emot Dysregul. 2016;3:1.

    Google Scholar 

  68. Zanarini MC, Frankenburg FR. A preliminary, randomized trial of psychoeducation for women with borderline personality disorder. J Personal Disord. 2008 Jun;22(3):284–90.

    Google Scholar 

  69. Zanarini MC, Conkey LC, Temes CM, Fitzmaurice GM. Randomized Controlled Trial of Web-Based Psychoeducation for Women With Borderline Personality Disorder. J Clin Psychiatry. 2017 Jul 11. pii: 16m11153.

  70. Blum N, St John D, Pfohl B, Stuart S, McCormick B, Allen J, et al. Systems training for emotional predictability and problem solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. Am J Psychiatry. 2008 Apr;165(4):468–78.

    Google Scholar 

  71. Black DW, Simsek-Duran F, Blum N, McCormick B, Allen J. Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program? Personal Ment Health. 2016 Aug;10(3):205–15.

    Google Scholar 

  72. Clarkin JF, Levy KN, Lenzenweger MF, Kernberg OF. Evaluating three treatments for borderline personality disorder: a multiwave study. Am J Psychiatry. 2007;164:922–8.

    Google Scholar 

  73. Giesen-Bloo J, van Dyck R, Spinhoven P, van Tilburg W, Dirksen C, van Asselt T, et al. Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy. Arch Gen Psychiatry. 2006;63:649–58.

    Google Scholar 

  74. Leppänen V, Hakko H, Sintonen H, Lindeman S. Comparing effectiveness of treatments for borderline personality disorder in communal mental health care: the Oulu BPD study. Community Ment Health J. 2016 Feb;52(2):216–27.

    Google Scholar 

  75. Gratz KL, Gunderson JG. Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behav Ther. 2006 Mar;37(1):25–35.

    Google Scholar 

  76. Simpson EB, Yen S, Costello E, Rosen K, Begin A, Pistorello J, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004 Mar;65(3):379–85.

    CAS  Google Scholar 

  77. Soler J, Pascual JC, Campins J, Barrachina J, Puidgemont D, Alvarez E, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005 Jun;162(6):1221–4.

    Google Scholar 

  78. Reyes-Lopez J, Ricardo-Gardell J, Armas-Castaneda G, Garcia-Anaya M, Arango-De Montis I, Gonzaleez-Olvera JJ, et al. Clinical improvement in patients with borderline personality disorder after treatment with repetitive transcranial magnetic stimulation: preliminary results. Rev Bras Psiquiatr. 2018 Jan-Mar;40(1):97–1044.

    Google Scholar 

  79. Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G. Attainment and Stability of Sustained Symptomatic Remission and Recovery Among Patients With Borderline Personality Disorder and Axis II Comparison Subjects: A 16-Year Prospective Follow-Up Study. Am J Psychiatry. 2012;169:476–83.

    Google Scholar 

  80. Skodol AE, Gunderson JG, Shea MT, McGlashan TH, Morey MC, Sanislow CA, et al. The collaborative longitudinal personality disorders study (CLPS): overview and implications. J Personal Disord. 2005;19:487–504.

    Google Scholar 

  81. Hansenne M. Psychologie de la personnalité. 4ème ed. De Boeck supérieur s.a.: Louvain-la-Neuve; 2013.

    Google Scholar 

  82. American Psychiatric Association. DSM-5 - Manuel diagnostique et statistique des troubles mentaux. Issy-les-Moulineaux: Elsevier Masson SAS; 2015.

Download references

Acknowledgments

I want to thank Marushka Dehaye (MD) for their support.

Code Availability

Not aplicable

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Erasme Hospital, Department of Psychiatry and Sleep Laboratory, Université libre de Bruxelles, Route de Lennik, 808-1070, Anderlecht, Belgium

    Anaïs Mungo, Matthieu Hein, Philippe Hubain & Gwenolé Loas

  2. Department of Psychiatry, CHC Liège – site Saint Vincent, Rocourt, Belgium

    Philippe Fontaine

Authors
  1. Anaïs Mungo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthieu Hein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Philippe Hubain
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gwenolé Loas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Philippe Fontaine
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Anaïs Mungo: principal investigator, conceived the study and drafted the protocol, performed the database searches, reviewed the titles and abstracts, performed the data extraction and.

Matthieur Hein: performed the data extraction, made substantial contributions to the revision of the manuscript.

Philippe Hubain: made substantial contributions to the revision of the manuscript.

Gwenole Loas: made substantial contributions to the revision of the manuscript.

Philippe Fontaine: conceived the study and drafted the protocol, made substantial contributions to the revision of the manuscript.

All authors have given final approval of the version to be published.

Corresponding author

Correspondence to Anaïs Mungo.

Ethics declarations

Competing Interests

The authors declare that they have no links of interest.

Ethical Approval

Not applicable.

Consent to Participate and for Publication

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOC 62 kb)

ESM 2

(DOC 31 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mungo, A., Hein, M., Hubain, P. et al. Impulsivity and its Therapeutic Management in Borderline Personality Disorder: a Systematic Review. Psychiatr Q 91, 1333–1362 (2020). https://doi.org/10.1007/s11126-020-09845-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11126-020-09845-z

Keywords

  • Borderline personality disorder
  • Impulsivity
  • Psychotherapy
  • Pharmacotherapy
  • Systematic review